ClinicalTrials.gg
Active, not recruitingNCT05071963Updated Aug 10, 2026

INSPIRE Pipeline™ Shield Post Approval Study

An observational study in Intracranial Aneurysm, sponsored by Medtronic Neurovascular Clinical Affairs. Active, not recruiting at 16 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Medtronic Neurovascular Clinical Affairs (part of Medtronic) · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
246
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Intracranial Aneurysm by Medtronic — 4 open to participants now, 5 under way, none of them phase 3. Intracranial Aneurysm · Medtronic.

Enrollment
4th of 10
246 · median 203
Started
2021
the only one that year
Observational
10 of 16
3 open now
Registered
15th of 16
by date

Among the 16 studies in Intracranial Aneurysm by Medtronic, this one is the 4th largest by enrollment of the 10 observational ones that give a count, is the only one that started in 2021, is one of 10 observational ones, and was the 15th registered.

Intracranial Aneurysm

418 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

4 of the 16 studies in Intracranial Aneurysm by Medtronic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 83 Intracranial Aneurysm studies recruiting now, 49 (59%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Intracranial Aneurysm by Medtronic, or all of them as a file.
02

Study summary

The purpose of the Pipeline™ Flex Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Shield PAS") is to collect on-label use data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Flex Embolization Device with Shield Technology™ ("Pipeline™ Shield Device") in a real-world post approval setting within the United States.

Read the detailed description

The INSPIRE Pipeline™ Shield Post Approval Study is an observational, prospective, multi-center, single-arm registry to collect on-label use data in patients undergoing treatment for intracranial aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™ according to the intended use.

The primary objective of this study is to evaluate the on-label use of the Pipeline™ Shield Device in patients undergoing treatment for intracranial aneurysms per institutional routine clinical care in a real-world post approval study setting in the U.S.

This study is conducted under the Product Surveillance Registry (NCT01524276) and is a sub-study to the therapy specific Neurovascular Product Surveillance Registry (NCT02988128).

03

Conditions studied

  • Intracranial Aneurysm

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients requiring treatment for intracranial aneurysms with the market approved Pipeline™ Flex Embolization Device with Shield Technology™ device are eligible for the registry

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient or legally authorized representative (LAR) provides authorization and/or consent per institution and geographical requirements.
  2. Patient is intended to receive or be treated with an eligible Medtronic product.
  3. Patient is consented within the enrollment window of the therapy received, as applicable.
  4. Patient or patient's legally authorized representative (LAR) has provided written using the IRB and Medtronic approved Informed Consent Form and agrees to comply with the study requirements. HIPAA/data protection authorization has been provided and signed by the patient (or patient's LAR).
  5. Patient has already been selected for endovascular treatment of the target aneurysm with the Pipeline™ Shield Device as the appropriate treatment per the Pipeline™ Shield Device Instructions For Use (IFU).

Exclusion criteria

Exclusion Criteria:

  1. Patient who is, or is expected to be, inaccessible for follow-up.
  2. Participation is excluded by local law.
  3. Patient is currently enrolled or plans to enroll in a concurrent drug/device study that may confound the PSR results (i.e. no required intervention that could affect interpretation of all-around product safety and/or effectiveness).
  4. Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study.
  5. Patient is for the device or procedure per the Pipeline™ Shield Device IFU.
  6. The Investigator determined that the health of the patient may be compromised by the patient's enrollment.
  7. Patient is enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval was obtained from Medtronic.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
246 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • DeviceTreatment of Intracranial Aneurysms

    Embolization of aneurysms using the Pipeline™ Flex Embolization Device with Shield Technology™

06

What researchers measure

Primary outcomes

  1. Incidence of the composite outcome (Occlusion of the target aneurysm, Significant parent artery stenosis, Retreatment of the target aneurysm) at 1 year post-procedure.

    Incidence at 1-year post-procedure of complete occlusion of the target aneurysm, significant parent artery stenosis ≤ 50%, and no retreatment of the target aneurysm.

    Time frame: 1 year

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 61 months after the start.

Of 105 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's planned 61 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2021
First posted
Oct 8, 2021
StartActual
Dec 20, 2021
Primary completionEst.
Jan 2027
CompletionEst.
Apr 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05071963
Responsible party
Sponsor
First posted
Oct 8, 2021
Start date
Dec 20, 2021
Primary completion
Jan 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Harsh Sancheti
study director · Medtronic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion